Nivolumab

Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Wednesday, November 1, 2023

PARIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced the presentation of immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors and recurrent glioblastoma at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place from November 1-5, 2023, in San Diego, California, and virtually.

Key Points: 
  • PARIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced the presentation of immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors and recurrent glioblastoma at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place from November 1-5, 2023, in San Diego, California, and virtually.
  • EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics™ peptide-based immunotherapy.
  • The poster details are as follows:
    Title: “EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1-19/SPENCER Study”
    In addition, research collaborator from Tübingen University, Germany, presents immune response data from the ongoing Phase 1/2 ROSALIE study of EO2401 in combination with nivolumab in recurrent glioblastoma.
  • Title: “Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1-18/ROSALIE study”
    All abstracts will subsequently be published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), Dec. 2023.

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Retrieved on: 
Saturday, November 4, 2023

The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.

Key Points: 
  • The Progression-Free Survival (PFS), Disease Control Rate (DCR), and ctDNA molecular response data in PERIO-01 patients in combination with nivolumab are encouraging for UMLM and for other indications under development.
  • At the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab (n=7), the median PFS was 11.7 months with an 81% DCR.
  • At the data cutoff as of September 29, 2023, 56 patients were enrolled, with each having received at least one dose of SD-101.
  • Dr. Katz added, “These data reflect additional validation of our innovative immunotherapy approach for liver and pancreas tumors.

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

Retrieved on: 
Monday, November 6, 2023

The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.

Key Points: 
  • The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy.
  • "We were delighted to present at SITC clinical data which reinforces data previously presented, suggesting that COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy", said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.
  • In addition, we presented data in metastatic breast cancer, another indication in which patients who typically do not respond to immunotherapy, derived clinical benefit from COM701 combinations."
  • I look forward to the results of the ongoing proof-of-concept study evaluating the combination of COM701, COM902 and pembrolizumab in platinum resistant ovarian cancer patients."

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

Retrieved on: 
Tuesday, October 31, 2023

Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.

Key Points: 
  • Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.
  • “The new data for the combination of visugromab with bispecific T-cell engagers provide strong scientific support for a synergistic effect in this novel therapeutic setting.
  • When investigating the involvement of additional cell adhesion pathway components downstream of GDF-15, SHP-1 was identified as a central mediator of GDF-15-related inhibition of T cell adhesion.
  • In addition, CatalYm recently announced an exploratory Phase 2 study , GDFather-NEO ( NCT06059547 ), evaluating visugromab in combination with neoadjuvant immunotherapy in first-line muscle-invasive bladder cancer.

Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

The data presented at SITC include initial safety and efficacy results from single agent therapy (n=13) in the dose escalation portion of the trial.

Key Points: 
  • The data presented at SITC include initial safety and efficacy results from single agent therapy (n=13) in the dose escalation portion of the trial.
  • “We’re pleased to share these first clinical data from our clinical trial of NDI-101150.
  • In a second poster at SITC, Nimbus is presenting new preclinical data which support the potential for both broad immunotherapeutic potential and best-in-class selectivity of NDI-101150 among publicly disclosed HPK1 inhibitor programs to date.
  • “The data presented at SITC reinforce the potential first-in-class and best-in-class profile of our HPK1 inhibitor, and we will continue to work to realize its possible benefits to patients with cancer.”

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Retrieved on: 
Monday, October 30, 2023

Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure.

Key Points: 
  • Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure.
  • “We know that approximately 20% to 25% of patients diagnosed with urothelial carcinoma will experience disease metastasis, and an additional 5% of patients present de novo with metastatic disease.
  • The OS and PFS data from CheckMate -901 were presented at the European Society for Medical Oncology (ESMO) Congress 2023 .
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -901 clinical trial.

Florida Cancer Specialists & Research Institute Physicians Contribute to Immunotherapy Treatment Advances at Global Meeting

Retrieved on: 
Friday, November 3, 2023

FORT MYERS, Fla., Nov. 3, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute (FCS) physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.

Key Points: 
  • FORT MYERS, Fla., Nov. 3, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute (FCS) physicians will present at the Society for Immunotherapy of Cancer Annual Meeting this week in San Diego.
  • They will join stakeholders across the immune-oncology field worldwide to advance the science, discover breakthroughs and enhance education on cancer immunotherapy, which uses the body's own immune system to find, target and fight many forms of the disease.
  • "Immunotherapy is one of the most promising and successful treatment areas for cancer, even at the most advanced stages, said Lucio N. Gordan, MD , FCS President & Managing Physician.
  • "Through our robust and far-reaching clinical trials research program, FCS continues to contribute to cutting-edge research that is providing hope and improving outcomes for cancer patients worldwide."

CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients

Retrieved on: 
Thursday, October 26, 2023

CatalYm today announced that the first patient has been dosed in the Phase 2 clinical trial, GDFather-NEO ( NCT06059547 ), evaluating its lead anti-GDF-15 antibody candidate, visugromab, in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).

Key Points: 
  • CatalYm today announced that the first patient has been dosed in the Phase 2 clinical trial, GDFather-NEO ( NCT06059547 ), evaluating its lead anti-GDF-15 antibody candidate, visugromab, in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).
  • The exploratory study expands visugromab’s clinical Phase 2 evaluation to a therapeutic front-line setting, building on the positive results from the ongoing GDFather-2 ( NCT04725474 ) trial in last-line metastatic patients with a range of advanced, treatment-resistant solid tumors.
  • In addition, the study will provide data on potential response-predictive biomarkers for patient stratification.
  • The trial will be led from Milan, Italy, and will enroll 30 patients in a 1:1 setting at four sites in Italy.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER

Retrieved on: 
Thursday, October 26, 2023

Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.

Key Points: 
  • Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.
  • The AccuTOXTM molecule can eradicate cancer cells via different mechanisms including the initiation of immunogenic cells death, endoplasmic reticulum stress and by causing direct damages to DNA.
  • AccuTOXTM triggers cancer tumor regression, Defence also recently demonstrated that encapsulated AccuTOXTM with chitosan nanoparticles triggers complete tumor regression in animals with pre-established solid lymphoma.
  • Further development and expanding applications on Defence’s leading AccuTOXTM therapeutic is ongoing and further news to be released upon results.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Retrieved on: 
Monday, October 23, 2023

BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.

Key Points: 
  • BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.
  • The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab.
  • The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).
  • Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.